Zydus Lifesciences Stock - Q3 revenue rises 30% as profit stays flat
19.06.2026 - 21:29:32 | ad-hoc-news.de
Edited by ad hoc news Friday Desk. Verified prior to publication on 06/19/2026, 19:25 UTC. Details in the imprint.
Zydus Lifesciences (INE010B01027) published a quarter that mixed solid top-line growth with a flat bottom line. Mint reported that Q3 revenue rose 30% year over year, while net profit stayed flat because of a one-time labor charge.
All news and analysis on Zydus Lifesciences stock
This hub collects price data, company updates, and market context for the Indian pharma group.
What Mint reported
Zydus Lifesciences was the subject of a Q3 results item on Mint, which cited revenue growth of 30% and flat profit. The report also linked the muted bottom line to a one-time labor charge.
The same report identified the company as a global life sciences business and pointed to a broader healthcare and pharma footprint. That fits the latest quarter, where the sales line carried the story more than earnings.
Analyst view today
Investing.com lists consensus coverage for Zydus Lifesciences at Neutral, based on 30 analysts. The same page shows an average 12-month target of INR 1,066.50, with a high of INR 1,457 and a low of INR 800.
The stock also sits close to that midpoint. That makes the latest quarter relevant for investors watching whether growth can translate more cleanly into profit.
What the company sells
Zydus Lifesciences develops, manufactures, and markets healthcare therapies across pharmaceuticals and related life sciences products. NSE describes the business under Pharmaceuticals, while LiveMint places it in Biotechnology and Drugs.
Where shares trade today
The shares of Zydus Lifesciences (INE010B01027) trade on NSE at INR 1,070.80 as of 06/19/2026, 16:00 IST.
Key facts on Zydus Lifesciences stock
- Company: Zydus Lifesciences Limited
- ISIN: INE010B01027
- Ticker: ZYDUSLIFE
- Venue: NSE
- Price (as of 06/19/2026, 16:00 IST): INR 1,070.80
- Sector / Industry: Pharmaceuticals
- Index membership: not live-verifiable
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
